keyword
MENU ▼
Read by QxMD icon Read
search

hepatitis c alcohol drugs

keyword
https://www.readbyqxmd.com/read/28793018/prevalence-of-hepatitis-b-and-c-virus-infection-among-alcoholic-individuals-importance-of-screening-and-vaccination
#1
Vanessa Faria Cortes, Angela Taveira, Helena Medina Cruz, Amanda Alves Reis, Jéssica Silva Cezar, Brener Santos Silva, Cintia Feliciano D'Assunção, Elisabeth Lampe, Livia Melo Villar
Drug users have been reported to have an increased risk for acquisition of viral hepatitis. This study aims to evaluate the prevalence of HBV and HCV infection and usefulness of saliva for HBsAg and anti-HCV detection in alcoholic patients.A total of 90 alcoholic patients were recruited in 2013. HBsAg and anti-HCV were tested in serum and saliva, anti-HBc and anti-HBs were tested in serum using commercial enzyme immunoassays (EIA).Using serum samples, anti-HCV, HBsAg, anti-HBc and anti-HBs prevalences were 5...
2017: Revista do Instituto de Medicina Tropical de São Paulo
https://www.readbyqxmd.com/read/28782502/society-for-maternal-fetal-medicine-smfm-consult-series-43-hepatitis-c-in-pregnancy-screening-treatment-and-management
#2
Brenna L Hughes, Charlotte M Page, Jeffrey A Kuller
In the United States, 1-2.5% of pregnant women are infected with hepatitis C virus (HCV), which carries an approximately 5% risk of transmission from mother to infant. HCV can be transmitted to the infant in utero or during the peripartum period, and infection during pregnancy is associated with increased risk of adverse fetal outcomes, including fetal growth restriction and low birth weight. The purpose of this document is to discuss the current evidence regarding HCV in pregnancy and to provide recommendations on screening, treatment, and management of this disease during pregnancy...
August 3, 2017: American Journal of Obstetrics and Gynecology
https://www.readbyqxmd.com/read/28777874/the-contribution-of-health-risk-behaviours-to-excess-mortality-in-american-adults-with-chronic-hepatitis-c-a-population-cohort-study
#3
H Innes, A McAuley, M Alavi, H Valerio, D Goldberg, S J Hutchinson
BACKGROUND: In resource-rich countries, chronic hepatitis C (CHC) infection is associated with a sizeable excess mortality risk. The extent to which this is due to: (a) the biological sequelae of CHC infection, versus b) a high concomitant burden of health risk behaviours (HRBs), is unclear. METHODS: We used data from the 1999-2010 US National-Health-and-Nutritional-Examination-Surveys (NHANES), which include detailed information on HRBs and CHC infection status...
August 4, 2017: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://www.readbyqxmd.com/read/28721344/exploring-patient-characteristics-and-barriers-to-hepatitis-c-treatment-in-patients-on-opioid-substitution-treatment-attending-a-community-based-fibro-scanning-clinic
#4
Des Crowley, Walter Cullen, Eamon Laird, John S Lambert, Tina Mc Hugh, Carol Murphy, Marie Claire Van Hout
BACKGROUND AND OBJECTIVES: Hepatitis C virus (HCV) infection is a major public health issue. There is substandard uptake in HCV assessment and treatment among people who inject drugs (PWID). Community fibroscanning is used to assess disease severity and target treatment. METHODS: A survey was administered to a cohort of chronically HCV infected patients attending a community fibroscanning clinic. Questions targeted diagnosis of HCV, suitability, willingness and barriers to engagement in treatment...
June 2017: Journal of Translational Internal Medicine
https://www.readbyqxmd.com/read/28719029/directly-observed-therapy-of-sofosbuvir-ribavirin-peginterferon-with-minimal-monitoring-for-the-treatment-of-chronic-hepatitis-c-in-people-with-a-history-of-drug-use-in-chennai-india-c-dot
#5
S S Solomon, M S Sulkowski, P Amrose, A K Srikrishnan, A M McFall, B Ramasamy, M S Kumar, S Anand, D L Thomas, S H Mehta
We assessed the feasibility of field-based directly observed therapy (DOT) with minimal monitoring to deliver HCV treatment to people with a history of drug use in Chennai, India. Fifty participants were randomized 1:1 to sofosbuvir+peginterferon alfa 2a+ribavirin (SOF+PR) for 12 weeks (Arm 1) vs sofosbuvir+ribavirin (SOF+R) for 24 weeks (Arm 2). SOF+R was delivered daily at participant chosen venues and weekly peginterferon injections at the study clinic. HCV RNA testing was performed to confirm active HCV infection and sustained virologic response 12 weeks after treatment completion (SVR12)...
July 18, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28702667/microengineered-cultures-containing-human-hepatic-stellate-cells-and-hepatocytes-for-drug-development
#6
Matthew D Davidson, David A Kukla, Salman R Khetani
In non-alcoholic steatohepatitis (NASH), hepatic stellate cells (HSC) differentiate into myofibroblast-like cells that cause fibrosis, which predisposes patients to cirrhosis and hepatocellular carcinoma. Thus, modeling interactions between activated HSCs and hepatocytes in vitro can aid in the development of anti-NASH/fibrosis therapeutics and lead to a better understanding of disease progression. Species-specific differences in drug metabolism and disease pathways now necessitate the supplementation of animal studies with data acquired using human liver models; however, current models do not adequately model the negative effects of primary human activated HSCs on the phenotype of otherwise well-differentiated primary human hepatocytes (PHHs) as in vivo...
August 14, 2017: Integrative Biology: Quantitative Biosciences From Nano to Macro
https://www.readbyqxmd.com/read/28683982/research-priorities-to-achieve-universal-access-to-hepatitis-c-prevention-management-and-direct-acting-antiviral-treatment-among-people-who-inject-drugs
#7
Jason Grebely, Julie Bruneau, Jeffrey V Lazarus, Olav Dalgard, Philip Bruggmann, Carla Treloar, Matthew Hickman, Margaret Hellard, Teri Roberts, Levinia Crooks, Håvard Midgard, Sarah Larney, Louisa Degenhardt, Hannu Alho, Jude Byrne, John F Dillon, Jordan J Feld, Graham Foster, David Goldberg, Andrew R Lloyd, Jens Reimer, Geert Robaeys, Marta Torrens, Nat Wright, Icro Maremmani, Brianna L Norton, Alain H Litwin, Gregory J Dore
Globally, it is estimated that 71.1 million people have chronic hepatitis C virus (HCV) infection, including an estimated 7.5 million people who have recently injected drugs (PWID). There is an additional large, but unquantified, burden among those PWID who have ceased injecting. The incidence of HCV infection among current PWID also remains high in many settings. Morbidity and mortality due to liver disease among PWID with HCV infection continues to increase, despite the advent of well-tolerated, simple interferon-free direct-acting antiviral (DAA) HCV regimens with cure rates >95%...
July 3, 2017: International Journal on Drug Policy
https://www.readbyqxmd.com/read/28644739/treatment-of-hepatitis-c-with-new-fixed-dose-combinations
#8
Vincent Soriano, José V Fernandez-Montero, Carmen de Mendoza, Laura Benitez-Gutierrez, José M Peña, Ana Arias, Pablo Barreiro
The advent of oral direct-acting antivirals (DAA) has revolutionized the hepatitis C virus (HCV) therapeutic landscape providing cure rates over 90%. However, a subset of patients remains at higher risk for treatment failure, including those infected with: i) genotype 3 and cirrhosis; ii) resistance-associated substitutions (RAS) occurring either as natural polymorphisms or selected after prior DAA failure; and iii) poor drug adherence associated with social disabilities (homeless, psychiatric illnesses, injection drug use, alcoholism, etc...
July 30, 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/28633998/changes-in-risk-behaviours-during-and-following-treatment-for-hepatitis-c-virus-infection-among-people-who-inject-drugs-the-activate-study
#9
Håvard Midgard, Behzad Hajarizadeh, Evan B Cunningham, Brian Conway, Markus Backmund, Philip Bruggmann, Julie Bruneau, Stefan Bourgeois, Adrian Dunlop, Graham R Foster, Margaret Hellard, Geert Robaeys, Maria C Thurnheer, Martin Weltman, Janaki Amin, Philippa S Marks, Sophie Quiene, Gregory J Dore, Olav Dalgard, Jason Grebely
BACKGROUND: The risk of hepatitis C virus (HCV) reinfection due to continued injecting risk behaviours might remain a barrier to HCV treatment among people who inject drugs. We aimed to evaluate changes in risk behaviours during and following HCV treatment among people with ongoing injecting drug use or receiving opioid substitution treatment (OST). METHODS: ACTIVATE was an international multicentre clinical trial conducted between 2012 and 2014. Participants with HCV genotypes 2/3 infection were treated with peg-interferon/ribavirin for 12 or 24 weeks and completed a self-administered behavioural questionnaire at each study visit...
June 17, 2017: International Journal on Drug Policy
https://www.readbyqxmd.com/read/28619394/understanding-real-world-adherence-in-the-directly-acting-antiviral-era-a-prospective-evaluation-of-adherence-among-people-with-a-history-of-drug-use-at-a-community-based-program-in-toronto-canada
#10
Kate Mason, Zoë Dodd, Mary Guyton, Paula Tookey, Bernadette Lettner, John Matelski, Sanjeev Sockalingam, Jason Altenberg, Jeff Powis
BACKGROUND: Direct acting antiviral (DAA) treatments for Hepatitis C (HCV) are now widely available with sustained virologic response (SVR) rates of >90%. A major predictor of response to DAAs is adherence, yet few real-world studies evaluating adherence among marginalized people who use drugs and/or alcohol exist. This study evaluates patterns and factors associated with non-adherence among marginalized people with a history of drug use who were receiving care through a primary care, community-based HCV treatment program where opiate substitution is not offered on-site...
June 12, 2017: International Journal on Drug Policy
https://www.readbyqxmd.com/read/28608973/high-hepatitis-c-cure-rates-among-black-and-non-black-hiv-infected-adults-in-an-urban-center
#11
Oluwaseun Falade-Nwulia, Catherine Sutcliffe, Juhi Moon, Geetanjali Chander, Tanyaporn Wansom, Jeanne Keruly, Jennifer Katzianer, Amy Nathanson, Jillian Marks, Shruti Mehta, David Thomas, Richard Moore, Mark Sulkowski
Background Hepatitis C virus (HCV) cure rates have been similar in patients with and without HIV co-infection; however, in the ION-4 study, black patients treated with ledipasvir/sofosbuvir were significantly less likely to achieve cure (90%) compared to non-black patients (99%). There are limited real world data on the effectiveness of oral direct acting antivirals (DAAs) in predominantly minority HIV/HCV co-infected populations. Methods We analyzed HCV treatment outcomes among 255 HCV co-infected patients initiating DAAs between February 2014 and March 2016 in an urban clinic in Baltimore, Maryland...
June 13, 2017: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://www.readbyqxmd.com/read/28603092/crosstalk-of-liver-immune-cells-and-cell-death-mechanisms-in-different-murine-models-of-liver-injury-and-its-clinical-relevance
#12
Hilal Ahmad Khan, Muhammad Zishan Ahmad, Junaid Ali Khan, Muhammad Imran Arshad
BACKGROUND: Liver inflammation or hepatitis is a result of pluripotent interactions of cell death molecules, cytokines, chemokines and the resident immune cells collectively called as microenvironment. The interplay of these inflammatory mediators and switching of immune responses during hepatotoxic, viral, drug-induced and immune cell-mediated hepatitis decide the fate of liver pathology. The present review aimed to describe the mechanisms of liver injury, its relevance to human liver pathology and insights for the future therapeutic interventions...
June 2017: Hepatobiliary & Pancreatic Diseases International: HBPD INT
https://www.readbyqxmd.com/read/28602867/effect-of-gangjihwan-on-hepatic-steatosis-and-inflammation-in-high-fat-diet-fed-mice
#13
Jong Seong Roh, Haerim Lee, Jonghoon Lim, Jeongjun Kim, Heejung Yang, Yooshik Yoon, Soon Shik Shin, Michung Yoon
ETHNOPHARMACOLOGICAL RELEVANCE: Gangjihwan (DF), a polyherbal drug composed of Ephedra intermedia Schrenk et C. A. Mayer (Ephedraceae), Lithospermum erythrorhizon Siebold et Zuccarini (Borraginaceae), and Rheum palmatum L. (Polygonaceae), is used to treat obesity in local Korean clinics. The constituents of DF have traditionally been reported to exert anti-obesity and anti-nonalcoholic fatty liver disease (NAFLD) effects. Thus, we investigated the effects of DF on obesity and NAFLD and the underlying mechanisms...
July 12, 2017: Journal of Ethnopharmacology
https://www.readbyqxmd.com/read/28595132/functionality-based-method-for-simultaneous-isolation-of-rodent-hepatic-sinusoidal-cells
#14
L Stradiot, S Verhulst, T Roosens, C I Øie, I M Moya, G Halder, I Mannaerts, L A van Grunsven
Chronic liver disease is the result of long term exposure to viruses or toxins such as alcohol, fat and drugs, and forms the basis for the development of liver fibrosis and primary liver cancer. In vitro and in vivo models are key to study the pathways involved in chronic liver disease and for the development of therapeutics. 3D co-culture systems are becoming the in vitro standard, which requires freshly isolated primary hepatic cells. We developed a novel isolation method to simultaneously isolate liver sinusoidal endothelial cells (LSECs), Kupffer cells (KCs) and hepatic stellate cells (HSCs)...
September 2017: Biomaterials
https://www.readbyqxmd.com/read/28588752/inducible-protein-10-as-a-predictive-marker-of-antiviral-hepatitis-c-treatment-a-systematic-review
#15
REVIEW
Bastian Neesgaard, Morten Ruhwald, Nina Weis
AIM: To investigate interferon-γ-inducible protein-10's (IP-10) potential to anticipate rapid (RVR)- and sustained virological responses (SVR) to chronic hepatitis C (CHC) treatment. METHODS: We included case series examining RVR or SVR in relation to 24 or 48 wk treatment for CHC, in patients treatment free for at least six months, with genotype 1 or 4, and in relation to 24 wk treatment for genotype 2 and 3, with pegylated interferon in combination with ribavirin...
May 18, 2017: World Journal of Hepatology
https://www.readbyqxmd.com/read/28587943/delivering-direct-acting-antiviral-therapy-for-hepatitis-c-to-highly-marginalised-and-current-drug-injecting-populations-in-a-targeted-primary-health-care-setting
#16
Phillip Read, Rebecca Lothian, Karen Chronister, Rosie Gilliver, John Kearley, Gregory J Dore, Ingrid van Beek
BACKGROUND: The Kirketon Road Centre (KRC) is a community-based public health facility in Sydney, Australia, that provides healthcare to people who inject drugs (PWID) care, including hepatitis C virus (HCV) treatment. From March 2016, the Australian Government has provided access to direct-acting antivirals (DAA) for adults with chronic HCV, without liver disease stage or drug and alcohol use restrictions. The aim of this study was to report DAA treatment outcomes among highly marginalised PWID treated at KRC...
June 3, 2017: International Journal on Drug Policy
https://www.readbyqxmd.com/read/28480064/systemic-therapy-for-advanced-hepatocellular-carcinoma-an-update
#17
REVIEW
Jasmin Radhika Desai, Sebastian Ochoa, Petra Alexandra Prins, Aiwu Ruth He
Advanced hepatocellular carcinoma (HCC) is a deadly disease with few systemic therapeutic options. Sorafenib is the only agent to be FDA approved for the first-line treatment of patients with HCC. This drug increases overall survival (OS) by 3 months compared with placebo (10.7 months with sorafenib vs. 7.7 months with placebo). More recently, the RESORCE trial demonstrated efficacy of regorafenib in the second-line treatment of HCC: OS was increased from 7.8 months with placebo to 10.6 months with regorafenib after patients experienced disease progression on sorafenib...
April 2017: Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/28476267/chronic-pain-among-patients-with-opioid-use-disorder-results-from-electronic-health-records-data
#18
Yih-Ing Hser, Larissa J Mooney, Andrew J Saxon, Karen Miotto, Douglas S Bell, David Huang
PURPOSE: To examine the prevalence of comorbid chronic pain among patients with opioid use disorder (OUD) and to compare other comorbidities (substance use disorder (SUD), mental health disorders, health/disease conditions) among patients in four categories: no chronic pain (No Pain), OUD prior to pain (OUD First), OUD and pain at the same time (Same Time), or pain condition prior to OUD (Pain First). METHODS: Using an electronic health record (EHR) database from 2006-2015, the study assessed 5307 adult patients with OUD in a large healthcare system; 35...
June 2017: Journal of Substance Abuse Treatment
https://www.readbyqxmd.com/read/28470665/pentamidine-blocks-hepatotoxic-injury-in-mice
#19
Enpeng Zhao, Ghulam Ilyas, Francesca Cingolani, Jae Ho Choi, François Ravenelle, Kathryn E Tanaka, Mark J Czaja
Toxin-induced liver diseases lack effective therapies despite increased understanding of the role factors such as an overactive innate immune response play in the pathogenesis of this form of hepatic injury. Pentamidine is an effective antimicrobial agent against several human pathogens, but studies have also suggested that this drug inhibits inflammation. This potential anti-inflammatory mechanism of action, together with the development of a new oral form of pentamidine isethionate VLX103, led to investigations of the effectiveness of this drug in the prevention and treatment of hepatotoxic liver injury...
May 3, 2017: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://www.readbyqxmd.com/read/28465155/effect-of-liver-disease-on-hepatic-transporter-expression-and-function
#20
REVIEW
Nilay Thakkar, Jason R Slizgi, Kim L R Brouwer
Liver disease can alter the disposition of xenobiotics and endogenous substances. Regulatory agencies such as the Food and Drug Administration and the European Medicines Evaluation Agency recommend, if possible, studying the effect of liver disease on drugs under development to guide specific dose recommendations in these patients. Although extensive research has been conducted to characterize the effect of liver disease on drug-metabolizing enzymes, emerging data have implicated that the expression and function of hepatobiliary transport proteins also are altered in liver disease...
April 30, 2017: Journal of Pharmaceutical Sciences
keyword
keyword
71298
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"